Vascular Biogenics reported -6513000 in Operating Profit for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Bluebird Bio BLUE:US $ -216.95M 23.88M
Capricor Therapeutics CAPR:US $ -4.32M 0.45M
Eleven Biotherapeutics EBIO:US 63.11M 88.51M
Epizyme EPZM:US $ -64140000 5.91M
Infinity Pharmaceuticals INFI:US $ -10.75M 0.5M
Newlink Genetics NLNK:US -7497000 1.17M
Prothena PRTA:US 109.23M 81.28M
Vascular Biogenics VBLT:US -6513000 1.51M